Dichloropane

Standard Drug Panel Inclusion

Dichloropane (RTI-111) is a phenyltropane-class stimulant structurally related to cocaine. It is not detected on standard immunoassay drug screens. While cocaine immunoassays target benzoylecgonine (the primary cocaine metabolite), dichloropane's modified tropane structure and distinct metabolic pathway mean it does not produce benzoylecgonine and will not cross-react with cocaine immunoassays.

Urine Detection

Dichloropane can be detected in urine for approximately 2 to 4 days. Its metabolic profile differs from cocaine, and standard cocaine metabolite screens will not detect it. Targeted LC-MS/MS methods with dichloropane-specific reference standards are required.

Blood and Saliva Detection

Blood detection windows are approximately 12 to 48 hours depending on dose and route of administration. Unlike cocaine, dichloropane is not rapidly hydrolyzed by plasma esterases, resulting in a longer parent compound half-life.

Hair Follicle Detection

Hair testing for dichloropane requires custom analytical methods. Standard cocaine/benzoylecgonine hair panels will not detect this compound. Specialized forensic laboratories with phenyltropane reference standards would be required.

Confirmatory Testing

LC-MS/MS is the preferred method for identifying dichloropane. The chlorine atoms provide distinctive isotope patterns in mass spectrometry, facilitating identification. GC-MS is also effective and may be preferred for its ability to detect the characteristic tropane fragmentation pattern.

Reagent Testing

Marquis reagent shows no reaction with dichloropane, unlike cocaine which produces no color change but dissolves. Scott reagent (cobalt thiocyanate), used specifically for cocaine presumptive testing, does not produce the characteristic blue color with dichloropane due to the structural modifications. Mandelin reagent may produce a faint orange color. Reagent testing can help distinguish dichloropane from cocaine but cannot provide positive identification.

Highly Limited Community Data

Dichloropane is not a compound with a substantial harm reduction community knowledge base. The limited experience data means that dose-response relationships, duration profiles in humans, and interaction risks are undocumented from a practical use perspective.

Apply Cocaine-Class Harm Reduction

The tropane scaffold and reuptake inhibitor mechanism make cocaine harm reduction principles the most applicable framework:

• Avoid combinations with stimulants, MAOIs, or serotonergic drugs
• Monitor cardiovascular symptoms (chest pain, palpitations, shortness of breath)
• Avoid use with pre-existing cardiovascular conditions
• Do not combine with alcohol or other recreational substances

SERT Activity Adds Serotonin Syndrome Risk

Unlike cocaine, dichloropane's high SERT affinity requires the additional precaution of treating it as a serotonergic compound: avoid MAOIs, SSRIs, and other entactogens due to serotonin syndrome risk.

No Established Dose Range

There is no community-established safe dose range for dichloropane. If used, start with extremely conservative doses to assess potency — this is a high-potency compound relative to cocaine.

Acute Toxicity Profile

No formal human toxicity studies exist for recreational doses. Based on cocaine class pharmacology and triple reuptake mechanism:

• Cardiovascular effects (tachycardia, hypertension, arrhythmia risk) are expected and dose-dependent
• High-potency DAT inhibition at high doses creates cocaine-like cardiovascular toxicity risk

Cocaine-Related Cardiomyopathy Concern

The PsychonautWiki data for dichloropane specifically flags the question of cocaine-related cardiomyopathy. Long-term cocaine use is associated with cardiomyopathy — a form of heart muscle disease — and whether dichloropane presents similar risks is explicitly flagged as unknown. This is a long-term toxicity concern relevant for anyone considering repeated use.

Serotonin Syndrome Risk

The high SERT affinity creates meaningful serotonin syndrome risk when combined with other serotonergic drugs — particularly MAOIs, SSRIs, or other serotonergic compounds. This is a distinct risk from pure cocaine analogs (which have lower SERT activity).

Tropane-Class Cardiovascular Risk

The tropane scaffold is associated with cardiovascular toxicity at high doses, consistent with the cocaine-class risk profile: coronary artery spasm, arrhythmia, QT prolongation.

Research Context

Because dichloropane is primarily a research chemical rather than a widely used recreational compound, documented cases of toxicity are rare in community harm reduction literature — but absence of documentation reflects absence of use data rather than absence of risk.

• Germany: Dichloropane is not a controlled substance under the BtMG (Narcotics Act) or the NpSG (New Psychoactive Substances Act). Technically it would fall under the definition of a medicine by §2 AMG (Medicines Act) because it induces a pharmacological effect. By a decision of the European Court of Justice, this definition was declared ineffective because it was not compatible with EU law. Dichloropane can be considered unregulated.

• Switzerland: Dichloropane is a controlled substance specifically named under Verzeichnis E.

• Turkey:** Dichloropane is a classed as drug and is illegal to possess, produce, supply, or import.

• United States: Dichloropane may be considered to be an analogue of cocaine under the Federal Analogue Act. The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.

• Responsible use

• Research chemicals

• Stimulants

• Cocaine

• Tropane alkaloids

• Dichloropane (Wikipedia)

• Dichloropane (Isomer Design)